CatalYm appoints Scott Clarke as CEO

German biotech CatalYm has appointed Scott Clarke as chief executive (CEO), noting that he brings over two decades of executive leadership experience in driving company growth, developing products, and shaping and executing transactions in the biopharmaceutical industry.

Mr Clarke takes the helm as CatalYm enters a new stage of corporate and clinical development, including the initiation of a broad Phase IIb program for its lead candidate, visugromab, in non-squamous non-small-cell lung cancer and additional tumor indications. Based in the USA, he will oversee both European Union and US operations.

“Scott Clarke is a fantastic addition to CatalYm’s leadership team. The company is in a strong position following its oversubscribed $150 million Series D financing and its recent publication in Nature of positive visugromab data. These events provide significant momentum for Scott’s start as CEO,” said CatalYm interim chairman Jon Edwards.” “We are confident that his experience in oncology and partnering will be a substantial asset as we initiate CatalYm’s broad Phase IIb program with visugromab in hard-to-treat, metastatic solid tumor indications,” he added.